Reflex seizures in children with malformations of cortical development tend to be refractory to anticonvulsant medications but may respond to surgical resection of focal lesions. (Palmini A et al. Epilepsia 2005; 46:1224 -1234 .
EFFECT OF COMBINED KETOGENIC DIET AND VALPROATE TREATMENT FOR INTRACTABLE SEIZURES
The safety and tolerability of ketogenic diet (KGD) and valproate (VPA) cotherapy in the treatment of intractable seizures were evaluated retrospectively at the Massachusetts General Hospital, Boston. The ages of a total of 71 patients were 7 months to 20 years (mean, 7 years). All had received the KGD, and 24 were treated concomitantly with VPA. Two patients (2.8%) developed pancreatitis after 4 months on the KGD alone. Adverse events affecting patients equally in the KGD/VPA and non-VPA groups included symptomatic acidosis (39.4%), nausea and vomiting (23.9%), hypertriglyceridemia (21.1%), infections (eg otitis media, URI) in 21%, lethargy (18.3%), and behavioral abnormalities and irritability (15.5%). Renal calculi affected 6.4% of the KGD alone group. Elevations in liver function tests occurred in 2 patients taking VPA cotherapy. Carnitine supplements were given to 19 patients on the diet, and no patient reported symptoms of carnitine deficiency. Treatment was continued at 1 year in 32 patients, 11 taking the combined KGD and VPA therapy. Reductions in seizure frequency at 1 year were 47% with >90% reduction, 25% with 50-90% reduction, and 29% with <50% reduction. Seizure control was not significantly different in the KGD and VPA cotherapy groups and was unrelated to the KGD fat to carbohydrate ratio.
The majority received a ratio of 4:1 at initiation of the diet, 17 had ratios of 3.5-3.9:1, and 12, ratios of 3-3. 
OMEGA-3 FATTY ACID SUPPLEMENTS FOR CHRONIC EPILEPSY
Omega-3 fatty acid (FA) supplements (lg EPA and 0.7g DHA daily) were used in the treatment of 58 patients with refractory epilepsy, in a 12-week double-blind, placebocontrolled trial conducted by researchers at the UCL Institute of Neurology, London, UK. In the first 6 weeks of treatment, a 50% reduction in seizures was obtained in 5 of 29 supplemented patients whereas none (0/27) showed benefit with placebo (P=0.087). In the second 6 weeks, this apparent initial trend toward significant difference in seizure control was not sustained: 4/30 in the supplemented group and 5/27 in placebo group showed reduction in seizure frequency. The need for intermittent therapy with diazepam did not differ between the two groups. Status epilepticus occurred in one patient in each group. FA supplements produced an expected increase in plasma EPA and DHA concentrations and a reciprocal fall in omega-6 arachidonic and linoleic acid concentrations. Antiepileptic drug levels were unaffected. (Yuen AWC, Sander JW, Fluegel D et al. COMMENT. Experimental studies in animals have shown that EPA and DHA as well as omega-6 FA will raise seizure thresholds, and omega-3 FA will lower plasma inflammatory mediators, which may lead to reduction in seizure susceptibility (Bailey EE et al. Epilepsy Behav 2005; 6:4-8) . In a recent report of the benefits of fatty acid supplements in children with reading disabilities and ADHD, a combination of omega-3 and -6 FA was recommended (Richardson AJ et al. Pediatrics 2005; 115:1360 -1366 Ped Neur Briefs May 2005; 19:33-34) . Future trials of FA supplements in patients with refractory epilepsy should perhaps include both omega-3 and -6 FA.
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